These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

817 related items for PubMed ID: 17582225

  • 1. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M.
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ, Prentice NP, Cousland G, Bonham J.
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):155-60. PubMed ID: 17600848
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC.
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [Abstract] [Full Text] [Related]

  • 6. Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
    Rosenblatt A, Samus QM, Onyike CU, Baker AS, McNabney M, Mayer LS, Brandt J, Lyketsos CG.
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):178-84. PubMed ID: 17676652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [Abstract] [Full Text] [Related]

  • 10. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
    Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Sameshima T, Kawahara T, Goto I, Shudo K, Kurayama S, Nakamura J, Okahara K, Mitsuyama Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):541-5. PubMed ID: 20184936
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT.
    Pharmacotherapy; 2007 Mar 16; 27(3):399-411. PubMed ID: 17316151
    [Abstract] [Full Text] [Related]

  • 13. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar 16; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 14. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I, Palmblad J, Wahlund LO, Schultzberg M, Basun H, Eriksdotter Jönhagen M.
    Dement Geriatr Cogn Disord; 2009 Mar 16; 27(5):481-90. PubMed ID: 19439966
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.
    CNS Drugs; 2010 Feb 16; 24(2):163-76. PubMed ID: 20088621
    [Abstract] [Full Text] [Related]

  • 17. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1538-44. PubMed ID: 18573585
    [Abstract] [Full Text] [Related]

  • 18. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, Fukuyama H, Kita T.
    J Neurol Sci; 2004 Oct 15; 225(1-2):135-41. PubMed ID: 15465097
    [Abstract] [Full Text] [Related]

  • 19. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C, Jiménez Caballero PE, Alfonso V, González-Adalid M.
    Dement Geriatr Cogn Disord; 2009 Oct 15; 28(3):196-205. PubMed ID: 19738386
    [Abstract] [Full Text] [Related]

  • 20. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.